What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) for obesity.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. Which dose of CagriSema participants will continue on is decided by chance. If participants get placebo in the main study, participants will get CagriSema in the extension study. Participants will take one injection of study medicine once a week. The study will last for about 3 years and 3 months.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
key Inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing the informed consent. * BMI ≥ 30.0 kilogram per square meter (kg/m\^2) at screening. * Participant has a wish to lose at least 25% of body weight within 80 weeks from randomisation. key Exclusion Criteria: * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimole per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes.
Study sites by state
California
- FDRC — Costa Mesa
- Linda Vista Health Care Ctr — San Diego
- Diablo Clinical Research, Inc. — Walnut Creek
Florida
- Northeast Research Institute — Fleming Island
- Jacksonville Ctr For Clin Res — Jacksonville
- South Broward Research LLC — Miramar
- Florida Inst For Clin Res LLC — Orlando
- Oviedo Medical Research, LLC — Oviedo
- Cnt for Diab,Obes, and Metab — Pembroke Pines
Georgia
- Hope Clin Res & Wellness — Conyers
- Endocrine Research Solutions — Roswell
Illinois
- Great Lakes Clinical Trials — Chicago
- Endeavor Health — Skokie
- Evanston Premier Hlthcr Res — Skokie
Indiana
- Midwest Inst For Clin Res — Indianapolis
Iowa
- Iowa Diab & Endo Res Center — West Des Moines
Michigan
- Northern Pines Hlth Ctr, PC — Buckley
Missouri
- StudyMetrix Research LLC — City of Saint Peters
- Amicis Centers of Clinical Research — St Louis
Montana
- Mercury Str Med Grp, PLLC — Butte
New York
- Southgate Medical Group, LLP — West Seneca
- Great Lakes Medical Research — Westfield
North Carolina
- University of North Carolina — Chapel Hill
- Medication Mgmnt, LLC_Grnsboro — Greensboro
- PharmQuest Life Sciences LLC — Greensboro
- Accellacare_NC — Raleigh
- Piedmont Healthcare/Research — Statesville
- Accellacare — Wilmington
Ohio
- New Venture Medical Research — Wadsworth
Oklahoma
- Lynn Institute of Norman — Norman
Rhode Island
- Clinical Res Collaborative — Cumberland
South Carolina
- Coastal Carolina Res Ctr — North Charleston
- Hillcrest Clinical Research — Simpsonville
- Spartanburg Medical Research — Spartanburg
Tennessee
- Holston Medical Group — Kingsport
- Clinical Research Associates — Nashville
Texas
- Amarillo Medical Specialists — Amarillo
- Velocity Clin Res, Dallas — Dallas
- PlanIt Research, PLLC — Houston
- Radiance Clinical Research — Lampasas
- DCOL Ctr for Clin Res — Longview
- Northeast Clinical Research of San Antonio — Schertz
Virginia
- Washington Cntr Weight Mgmt — Arlington
- Health Res of Hampton Roads — Newport News
- Selma Medical Associates — Winchester
Washington
- Rainier Clin Res Ctr Inc — Renton
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)